Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Neural tube defect risk from dolutegravir drops as clinical experience grows

Publish date:: July 8, 2020

Key clinical point: Expanded patient experience showed a very small increased risk for neural tube defects after dolutegravir treatment at the time of conception.

Major finding: Mothers treated with dolutegravir when they conceived had a 0.19% incidence of neonates born with a neural tube defect.

Study details: Tsepamo, a prospective observational study that’s included 156,846 women infected with HIV who have delivered neonates at any of 18 sites in Botswana during 2014-2020.

Disclosures: The study had no commercial funding. Dr. Zash has been a researcher in studies funded by CytoDyn, Fulcrum, and Gilead. Dr. Gandhi had no commercial disclosures.

Source: Zash R. AIDS 2020.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Infectious Diseases

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

Vaccine-preventable infection risk high for pediatric hematopoietic cell transplantation recipients,

Three genes could predict congenital Zika infection susceptibility,

Obesity, hypoxia predict severity in children with COVID-19,

Two consecutive negative FUBC results clear S. aureus bacteremia,